WO2002026265A3 - Pegylated interleukin-10 - Google Patents
Pegylated interleukin-10 Download PDFInfo
- Publication number
- WO2002026265A3 WO2002026265A3 PCT/US2001/042431 US0142431W WO0226265A3 WO 2002026265 A3 WO2002026265 A3 WO 2002026265A3 US 0142431 W US0142431 W US 0142431W WO 0226265 A3 WO0226265 A3 WO 0226265A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peg
- pegylated
- interleukin
- mono
- pegylated interleukin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001296962A AU2001296962A1 (en) | 2000-09-29 | 2001-09-28 | Pegylated interleukin-10 |
AT01977878T ATE516820T1 (en) | 2000-09-29 | 2001-09-28 | PEGYLATED INTERLEUKIN 10 |
EP01977878A EP1324779B1 (en) | 2000-09-29 | 2001-09-28 | Pegylated interleukin-10 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23659600P | 2000-09-29 | 2000-09-29 | |
US60/236,596 | 2000-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002026265A2 WO2002026265A2 (en) | 2002-04-04 |
WO2002026265A3 true WO2002026265A3 (en) | 2003-01-23 |
Family
ID=22890150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/042431 WO2002026265A2 (en) | 2000-09-29 | 2001-09-28 | Pegylated interleukin-10 |
Country Status (7)
Country | Link |
---|---|
US (9) | US7052686B2 (en) |
EP (2) | EP2295450B1 (en) |
AT (1) | ATE516820T1 (en) |
AU (1) | AU2001296962A1 (en) |
ES (1) | ES2367891T3 (en) |
HK (1) | HK1154874A1 (en) |
WO (1) | WO2002026265A2 (en) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238368B2 (en) | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
DK1173222T3 (en) | 1999-04-23 | 2007-01-29 | Alza Corp | Conjugate with a cleavable bond for use in a liposome |
US7303760B2 (en) | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
WO2002026265A2 (en) * | 2000-09-29 | 2002-04-04 | Schering Corporation | Pegylated interleukin-10 |
MEP35608A (en) * | 2002-01-18 | 2011-02-10 | Biogen Idec Inc | Polyalkylene polymer compounds and uses thereof |
WO2004044006A1 (en) * | 2002-11-14 | 2004-05-27 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
US20060127357A1 (en) * | 2002-11-29 | 2006-06-15 | Roncarolo Maria G | Rapamycin and il-10 for the treatment of immune diseases |
AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
CN100415801C (en) * | 2003-10-28 | 2008-09-03 | 北京键凯科技有限公司 | Polyethylene glycol amino acid N-internal ring carbonyl anhydride active derivatives, and medicinal bonding compound and gel thereof |
AU2005286662B2 (en) | 2004-09-23 | 2011-10-06 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
JP2008530163A (en) * | 2005-02-16 | 2008-08-07 | マイクロメット アクツィエン ゲゼルシャフト | Use of activated polymers for the separation of protein and polypeptide multimers |
CN101163716B (en) * | 2005-04-30 | 2011-09-07 | 成都生物制品研究所 | Interleukin-6 polyethylene glycol conjugate and its preparing method and use |
US20180311071A1 (en) | 2005-10-21 | 2018-11-01 | Daniel R. BURNETT | Method and apparatus for peritoneal oxygenation |
CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
US20100028328A1 (en) * | 2006-06-12 | 2010-02-04 | Therakine, Ltd. | Topical treatment for diseases of eye surface |
US20080081031A1 (en) * | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
EP3156415A1 (en) | 2006-11-22 | 2017-04-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
CA2674354A1 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
EP2111228B1 (en) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis |
KR20150116465A (en) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon/glp-1 receptor co-agonists |
WO2009003188A2 (en) * | 2007-06-27 | 2008-12-31 | Cedars-Sinai Medical Center | N-terminal specific chemical labeling for proteomics applications |
US20090094368A1 (en) * | 2007-10-08 | 2009-04-09 | Steven Francis Best | Instant messaging general queue depth management |
CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
CA2702289A1 (en) * | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
US20110065633A1 (en) * | 2008-01-30 | 2011-03-17 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
EP2095829A1 (en) * | 2008-02-27 | 2009-09-02 | LEK Pharmaceuticals D.D. | Selenium containing modifying agents and conjugates |
JP2011520961A (en) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | Scaffold domain protein based on multivalent fibronectin |
CN104447980A (en) * | 2008-06-17 | 2015-03-25 | 印第安纳大学研究及科技有限公司 | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
MX2010013454A (en) | 2008-06-17 | 2011-01-21 | Tion Indiana University Res And Technology Corpora | Glucagon/glp-1 receptor co-agonists. |
AU2009274425B2 (en) * | 2008-06-17 | 2014-05-15 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
TWI496582B (en) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
EP2379115B1 (en) * | 2008-12-17 | 2017-10-25 | Merck Sharp & Dohme Corp. | Mono- and di-peg il-10 production; and uses |
AU2013205045B2 (en) * | 2008-12-17 | 2015-10-15 | Merck Sharp & Dohme Corp. | Mono- and di-peg IL-10 production; and uses |
CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
CN102245624B (en) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | Insulin prodrug based on amide |
WO2010071807A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
PE20120331A1 (en) * | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | MEDICINAL AGENTS LINKED TO DIPEPTIDE |
WO2010083154A2 (en) * | 2009-01-13 | 2010-07-22 | The Uab Research Foundation | Heterofunctional segment-poly(ethylene glycol) polymers as delivery vehicles |
CN102459325B (en) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | Gip receptor-active glucagon compounds |
IN2012DN00863A (en) | 2009-07-31 | 2015-07-10 | Medarex Inc | |
EP2480578A4 (en) * | 2009-09-25 | 2013-04-17 | Vybion Inc | Polypeptide modification |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
EP2569000B1 (en) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
US8940860B2 (en) | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
WO2011163460A1 (en) * | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor |
EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | Amide based glucagon superfamily peptide prodrugs |
EP2585102B1 (en) | 2010-06-24 | 2015-05-06 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
CN103458920B (en) | 2010-12-22 | 2016-07-06 | 印第安那大学科技研究公司 | Show the glucagon analogs of GIP receptor active |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
RU2014101697A (en) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Glucagon receptor coagonists / GLP-1 |
MX347703B (en) | 2011-06-22 | 2017-05-09 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists. |
WO2013003593A1 (en) | 2011-06-28 | 2013-01-03 | Alternative Innovative Technologies Llc | Methods of use of hsp70 for increased performance or hsp70 related disorders |
RU2014114849A (en) | 2011-10-14 | 2015-11-20 | Алтернатив Инновейтив Текнолоджиз Ллц | Degradation-resistant derivatives of proteins of heat shock-70 (btsh70) and methods of their application (options) |
CN104053670A (en) | 2011-10-31 | 2014-09-17 | 百时美施贵宝公司 | Fibronectin binding domains with reduced immunogenicity |
WO2013074910A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
WO2013101509A2 (en) | 2011-12-15 | 2013-07-04 | Alternative Innovative Technologies Llc | Hsp70 fusion protein conjugates and uses thereof |
CN104114183A (en) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | CTP-based insulin analogs for treatment of diabetes |
CA2868883C (en) | 2012-03-30 | 2022-10-04 | Sorrento Therapeutics Inc. | Fully human antibodies that bind to vegfr2 |
EP3553086A1 (en) | 2012-05-31 | 2019-10-16 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
WO2013192129A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
CA2877573A1 (en) | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind c-met |
US9315579B2 (en) | 2012-06-22 | 2016-04-19 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CCR2 |
EP3395358B1 (en) | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
JP6538645B2 (en) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Insulin-incretin complex |
JP2016519108A (en) * | 2013-04-18 | 2016-06-30 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Method for using interleukin-10 for the treatment of diseases and disorders |
EP2989240A4 (en) * | 2013-04-24 | 2016-10-19 | Armo Biosciences Inc | Interleukin-10 compositions and uses thereof |
JP2016528879A (en) | 2013-06-17 | 2016-09-23 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Methods for assessing protein identity and stability |
JP6509867B2 (en) * | 2013-08-30 | 2019-05-08 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Methods of using interleukin-10 to treat diseases and disorders |
MX2016005614A (en) | 2013-11-01 | 2016-12-09 | Spherium Biomed S L | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents. |
RU2016122957A (en) | 2013-11-11 | 2017-12-19 | Армо Байосайенсиз, Инк. | Methods of using interleukin-10 for the treatment of diseases and disorders |
CN109498815B (en) * | 2013-12-30 | 2022-07-22 | 江苏众红生物工程创药研究院有限公司 | Chemical modifier of recombinant human kallikrein and application thereof |
US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
AU2015305894A1 (en) | 2014-08-22 | 2017-04-06 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CXCR3 |
WO2016049174A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Lipidated amide-based insulin prodrugs |
ES2822994T3 (en) | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Incretin-insulin conjugates |
KR20170068553A (en) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | Interleukin-15 compositions and uses thereof |
JP6675394B2 (en) | 2014-10-22 | 2020-04-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Use of interleukin-10 for the treatment of diseases and disorders |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
JP7121496B2 (en) | 2015-05-28 | 2022-08-18 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Pegylated interleukin-10 for use in cancer therapy |
WO2016196211A1 (en) | 2015-05-29 | 2016-12-08 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN108025040A (en) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | The method that disease and illness are treated using interleukin-10 |
UA125337C2 (en) | 2015-11-18 | 2022-02-23 | Мерк Шарп І Доум Корп. | Ctla4 binders |
BR112018010085A2 (en) | 2015-11-18 | 2018-11-13 | Merck Sharp & Dohme | pd1 / ctla4 binders |
SG11201804178YA (en) | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
US11045547B2 (en) | 2015-12-16 | 2021-06-29 | Merck Sharp & Dohme Corp. | Anti-LAG3 antibodies and antigen-binding fragments |
US20180369337A1 (en) * | 2016-01-05 | 2018-12-27 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
MX2018007295A (en) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same. |
CN116333124A (en) | 2016-01-29 | 2023-06-27 | 索伦托药业有限公司 | Antigen binding proteins that bind to PD-L1 |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
KR20190091325A (en) | 2016-12-07 | 2019-08-05 | 프로제너티, 인크. | Gastrointestinal tract detection methods, devices and systems |
EP3585411A4 (en) * | 2017-02-21 | 2020-12-16 | The Regents Of The University Of Michigan | Il-22bp compositions and method for the treatment of disease therewith |
CA3054156A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
US20200353050A1 (en) | 2017-11-10 | 2020-11-12 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors |
US20210347842A1 (en) | 2018-06-19 | 2021-11-11 | Eli Lilly And Company | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
WO2020106750A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
MX2021012813A (en) * | 2019-04-26 | 2022-03-17 | Prolynx Llc | Slow-release cytokine conjugates. |
MX2022002337A (en) | 2019-08-27 | 2022-06-08 | Tonix Pharma Ltd | Modified tff2 polypeptides. |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
GB202003428D0 (en) | 2020-03-10 | 2020-04-22 | Univ Dundee | IL-10 mutiens |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006058A1 (en) * | 1993-08-24 | 1995-03-02 | Polymasc Pharmaceuticals Plc | Polymer modification |
WO1996011953A1 (en) * | 1994-10-12 | 1996-04-25 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1999032134A1 (en) * | 1997-12-19 | 1999-07-01 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
WO2001058950A1 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | Improved interleukin 10 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US591974A (en) * | 1897-10-19 | Bicycle-brake | ||
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
JPH0630164B2 (en) * | 1985-12-16 | 1994-04-20 | キヤノン株式会社 | Optical head device |
JPS63152393A (en) | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | Glycosyl derivative |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
US5032396A (en) | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
US6217857B1 (en) | 1989-06-28 | 2001-04-17 | Schering Corporation | Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof |
US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP3260368B2 (en) | 1991-01-16 | 2002-02-25 | シェリング・コーポレーション | Treatment of neoplastic disease with interleukin-10 |
WO1992012726A1 (en) | 1991-01-16 | 1992-08-06 | Schering Corporation | Use of interleukin-10 in adoptive immunotherapy of cancer |
US6277635B1 (en) | 1992-03-04 | 2001-08-21 | Schering Corporation | Use of interleukin-10 to produce a population of suppressor cells |
US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
WO1994022473A1 (en) | 1993-04-01 | 1994-10-13 | University Of Washington | Use of interleukin 7 to improve vaccine potency |
US5665345A (en) | 1993-05-24 | 1997-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting viral replication using IL-10 |
SK8396A3 (en) | 1993-07-26 | 1997-03-05 | Schering Corp | Antagonists and agonists of human interleukin-10 |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
NZ259584A (en) | 1994-01-20 | 1998-01-26 | Schering Corp | Cancer treatment using interleukin 10 activated peripheral blood mononuclear cells optionally combined with il-10 alone or in combination with il-2 or alpha interferon (alpha-ifn), to stimulate peripheral blood mononuclear cells |
US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5866134A (en) | 1995-03-24 | 1999-02-02 | Schering Corporation | Method for enhancing the antibody response to specific antigens with Interleukin-10 |
US5770190A (en) | 1995-07-14 | 1998-06-23 | Schering Corporation | Method of treatment of acute leukemia with inteleukin-10 |
GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
US5744451A (en) * | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5759859A (en) | 1996-07-15 | 1998-06-02 | United States Of America As Represented By The Secretary Of The Army | Sensor and method for detecting trace underground energetic materials |
US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
ES2211033T3 (en) | 1998-01-07 | 2004-07-01 | Debio Recherche Pharmaceutique S.A. | DEGRADABLE HETEROBIFUNCTIONAL POLYETHYLENGLYCOL ACRYLATES AND GELS AND CONJUGATES DERIVED FROM SUCH ACRYLATES |
US5908921A (en) * | 1998-11-03 | 1999-06-01 | Eastman Kodak Company | Method of manufacturing gelatin |
US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
AU5827000A (en) | 1999-07-16 | 2001-02-05 | Maria Teresa Bejarano | Viral il-10 uses |
US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
US20030186386A1 (en) * | 2000-02-11 | 2003-10-02 | Hansen Christian Karsten | Interleukin 10 |
WO2002026265A2 (en) | 2000-09-29 | 2002-04-04 | Schering Corporation | Pegylated interleukin-10 |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
WO2002085300A2 (en) | 2001-04-23 | 2002-10-31 | The Regents Of The University Of California | Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
EP1276028A1 (en) | 2001-07-09 | 2003-01-15 | Telefonaktiebolaget L M Ericsson (Publ) | Status indication detection device and method |
GB0212648D0 (en) | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
EP1391513A1 (en) | 2002-08-08 | 2004-02-25 | Cytheris | IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
WO2004044006A1 (en) | 2002-11-14 | 2004-05-27 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
US20060127357A1 (en) | 2002-11-29 | 2006-06-15 | Roncarolo Maria G | Rapamycin and il-10 for the treatment of immune diseases |
AU2003303636B2 (en) | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
EP2261244A3 (en) | 2003-04-15 | 2011-02-23 | Glaxosmithkline LLC | Human il-18 substitution mutants and their conjugates |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
WO2005033307A1 (en) | 2003-09-30 | 2005-04-14 | Kyowa Hakko Kogyo Co., Ltd. | Novel refolding method and protein obtained by the method |
EP1702068B1 (en) | 2003-11-28 | 2010-02-10 | The University Of Sydney | Latent phase viral interleukin-10-(vii-10) and uses thereof |
BRPI0418286A (en) | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | il-7 fusion proteins |
EP1819728B1 (en) | 2004-12-09 | 2010-04-21 | MERCK PATENT GmbH | Il-7 variants with reduced immunogenicity |
WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
WO2006119170A2 (en) | 2005-05-02 | 2006-11-09 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
CA2609543C (en) | 2005-05-31 | 2015-03-24 | Avigen, Inc. | Mutant il-10 |
EP1746161A1 (en) | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
ATE491722T1 (en) | 2005-10-04 | 2011-01-15 | Zymogenetics L L C | PRODUCTION AND PURIFICATION OF IL-29 |
WO2007061657A2 (en) | 2005-11-14 | 2007-05-31 | The Brigham & Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
US20080081031A1 (en) | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
AU2007328206B2 (en) | 2006-12-04 | 2013-08-01 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
EP2959917A3 (en) | 2007-10-19 | 2016-02-24 | The Regents of The University of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
SG186302A1 (en) | 2010-06-16 | 2013-02-28 | Abbott Lab | Comparison of protein samples |
US8759617B2 (en) | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
MX2017011562A (en) | 2015-03-11 | 2018-05-11 | Nektar Therapeutics | Conjugates of an il-7 moiety and an polymer. |
-
2001
- 2001-09-28 WO PCT/US2001/042431 patent/WO2002026265A2/en active Application Filing
- 2001-09-28 EP EP10013313.1A patent/EP2295450B1/en not_active Expired - Lifetime
- 2001-09-28 AU AU2001296962A patent/AU2001296962A1/en not_active Abandoned
- 2001-09-28 EP EP01977878A patent/EP1324779B1/en not_active Expired - Lifetime
- 2001-09-28 ES ES01977878T patent/ES2367891T3/en not_active Expired - Lifetime
- 2001-09-28 US US09/967,223 patent/US7052686B2/en not_active Expired - Lifetime
- 2001-09-28 AT AT01977878T patent/ATE516820T1/en active
-
2006
- 2006-05-25 US US11/440,962 patent/US20060210534A1/en not_active Abandoned
-
2008
- 2008-08-28 US US12/200,486 patent/US20080317707A1/en not_active Abandoned
-
2009
- 2009-11-18 US US12/620,854 patent/US20100297069A1/en not_active Abandoned
-
2010
- 2010-11-19 US US12/950,329 patent/US20110064690A1/en not_active Abandoned
-
2011
- 2011-08-26 US US13/218,929 patent/US8697045B2/en not_active Expired - Fee Related
- 2011-08-30 HK HK11109139.0A patent/HK1154874A1/en not_active IP Right Cessation
-
2014
- 2014-02-21 US US14/186,954 patent/US9238079B2/en not_active Expired - Fee Related
-
2015
- 2015-12-10 US US14/965,607 patent/US9925245B2/en not_active Expired - Lifetime
-
2018
- 2018-02-06 US US15/889,953 patent/US10471126B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006058A1 (en) * | 1993-08-24 | 1995-03-02 | Polymasc Pharmaceuticals Plc | Polymer modification |
WO1996011953A1 (en) * | 1994-10-12 | 1996-04-25 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1999032134A1 (en) * | 1997-12-19 | 1999-07-01 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
WO2001058950A1 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | Improved interleukin 10 |
Also Published As
Publication number | Publication date |
---|---|
US20110305665A1 (en) | 2011-12-15 |
HK1154874A1 (en) | 2012-05-04 |
US10471126B2 (en) | 2019-11-12 |
ES2367891T3 (en) | 2011-11-10 |
AU2001296962A1 (en) | 2002-04-08 |
EP2295450A1 (en) | 2011-03-16 |
EP2295450B1 (en) | 2015-01-28 |
EP1324779B1 (en) | 2011-07-20 |
US20080317707A1 (en) | 2008-12-25 |
ATE516820T1 (en) | 2011-08-15 |
US8697045B2 (en) | 2014-04-15 |
US9238079B2 (en) | 2016-01-19 |
US20160166647A1 (en) | 2016-06-16 |
US20110064690A1 (en) | 2011-03-17 |
US20060210534A1 (en) | 2006-09-21 |
US20180250363A1 (en) | 2018-09-06 |
US7052686B2 (en) | 2006-05-30 |
WO2002026265A2 (en) | 2002-04-04 |
US9925245B2 (en) | 2018-03-27 |
EP1324779A2 (en) | 2003-07-09 |
US20020044921A1 (en) | 2002-04-18 |
US20100297069A1 (en) | 2010-11-25 |
US20140227223A1 (en) | 2014-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002026265A3 (en) | Pegylated interleukin-10 | |
WO2001044286A3 (en) | Five-helix protein | |
CY1119848T1 (en) | INSULATED TETRAMIC URINATION | |
EP1085089A3 (en) | Human cyclic nucleotide phosphodiesterase | |
WO2000021574A3 (en) | Site-directed dual pegylation of proteins | |
WO2002014525A3 (en) | Expression vector using for animal cell | |
WO2000007629A3 (en) | Peg-urate oxidase conjugates and use thereof | |
WO2003048334A3 (en) | Immunocytokines with modulated selectivity | |
IL197339A (en) | Recombinant uricase chimeric protein, a conjugate comprising the protein and pharmaceutical compositions comprising the same | |
CA2305013A1 (en) | Fusion proteins comprising hiv-1 tat and/or nef proteins | |
EP1172114A3 (en) | Stable concentrated insulin preparations for pulmonary delivery | |
WO1999004820A3 (en) | Cytolysis of target cells by superantigen conjugates inducing t-cell activation | |
WO2003020932A1 (en) | Novel secretory proteins and dna thereof | |
AU2001290312A1 (en) | Peg-modified erythropoietin | |
EP1185545A4 (en) | Cd4-independent hiv envelope proteins as vaccines and therapeutics | |
WO2003048205A3 (en) | Novel proteins with il-6 inhibiting activity | |
WO2003089458A3 (en) | Conjugates of membrane translocating agents and pharmaceutically active agents | |
WO1996034964A3 (en) | Stable variant hk2 polypeptide | |
WO2003049699A3 (en) | Novel monofunctional polyethylene glycol aldehydes | |
WO2002044197A3 (en) | Cytokine receptor binding peptides | |
WO2002038612A3 (en) | Canine and feline tumour-associated antigen 5t4 | |
CA2340934A1 (en) | Novel collectin | |
MXPA02002489A (en) | Monomeric analogues of human insulin. | |
CA2406884A1 (en) | Novel collectins | |
EP1057490A3 (en) | Use of tranexamic acid for the preparation of a human fibrinogen composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001977878 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001977878 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |